Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Int Psychogeriatr. Author manuscript; available in PMC 2009 June 8.
Published in final edited form as:
PMCID: PMC2692675

Vascular Factors and Risk for Neuropsychiatric Symptoms in Alzheimer’s Disease: The Cache County Study



To examine, in an exploratory analysis, the association between vascular conditions and the occurrence of neuropsychiatric symptoms (NPS) in a population-based sample of incident Alzheimer’s disease (AD).


The sample consisted of 254 participants, identified through two waves of assessment. NPS were assessed using the Neuropsychiatric Inventory. Prior to the onset of AD, data regarding a history of stroke, hypertension, hyperlipidemia, heart attack or CABG, and diabetes were recorded. Logistic regression procedures were used to examine the relationship of each vascular condition to individual neuropsychiatric symptoms. Covariates considered were age, gender, education, APOE genotype, dementia severity, and overall health status.


One or more NPS were observed in 51.0% of participants. Depression was most common (25.8%), followed by apathy (18.6%), and irritability (17.7%). Least common were elation (0.8%), hallucinations (5.6%), and disinhibition (6.0%). Stroke prior to the onset of AD was associated with increased risk of delusions (OR=4.76, p=0.02), depression (OR=3.87, p=0.03), and apathy (OR=4.48, p=0.02). Hypertension was associated with increased risk of delusions (OR=2.34, p=0.02), anxiety (OR=4.10, p=0.002), and agitation/aggression (OR=2.82, p=0.01). No associations were observed between NPS and diabetes, hyperlipidemia, heart attack or CABG, or overall health.


Results suggest that a history of stroke and hypertension increase the risk of specific NPS in patients with AD. These conditions may disrupt neural circuitry in brain areas involved in NPS. Findings may provide an avenue for reduction in occurrence of NPS through the treatment or prevention of vascular risk conditions.

Keywords: dementia, Alzheimer, neuropsychiatric, disturbance, risk factors, vascular


Neuropsychiatric symptoms (NPS) such as depression, anxiety, delusions, and hallucinations commonly occur in Alzheimer’s disease (AD), the most common form of dementia in late life. Evidence suggests that between 60% and 90% of individuals with AD experience at least one disturbance during the course of their illness (e.g., Steinberg, 2006; Ikeda et al., 2004; Brodaty et al., 2001). They contribute to greater caregiver and patient distress (e.g., Craig et al., 2005; Danhauer, 2004), more costly interventions (e.g., Beeri et al., 2002; Finkel, 2000), and accelerated cognitive and functional decline (e.g., Boyle et al., 2003; Copeland et al., 2003; Holtzer et al., 2003). Given such high rates of occurrence and their serious impact, it is important to understand what contributes to the development of NPS.

Previous studies have identified a number of factors that increase the risk and modify the rate of NPS among individuals with AD. Increasing the risk for depression are older age, female gender (e.g., Gilley et al., 2004), and less education (e.g., Harwood et al., 2000). Increasing the risk for apathy is greater severity of cognitive and functional impairment (e.g., Boyle et al., 2003; Starkstein et al., 2001) and older age (e.g., Starkstein et al., 2006). Higher risk of agitation and aggression in AD are also associated with increasing cognitive and functional impairment (e.g., Holtzer et al., 2003; Copeland et al., 2003), older age (e.g., Tsai et al., 1996), and less education (e.g., Gabryelewicz et al., 2002). Psychotic symptoms, such as delusions or hallucinations, have been associated with more severe cognitive and functional impairment (e.g., Harwood et al., 2000; Paulsen et al., 2000), female gender (e.g., Leroi et al., 2003), and older age (e.g., Bassiony et al., 2000). Some studies have reported that genetic factors, specifically the E4 allele of the Apolipoprotein E (APOE), confer an increased risk for NPS in AD, including aggression, depression, and psychosis (e.g., van der Flier et al., 2007; Craig et al., 2004). However, the majority of studies have reported no relationship between APOE genotype and neuropsychiatric disturbances (e.g., Hirono et al., 1999; Levy et al., 1999).

Little is known about the relationship between modifiable risk factors, such as medical and health-related conditions and NPS in AD. Vascular conditions, such as hypertension, hyperlipidemia, and stroke, are of particular interest because they are common in the elderly and have been found to be risk factors for NPS among individuals without AD. Few studies, have examined the association between vascular conditions and NPS among individuals with AD, but a limited number of studies suggests that cerebrovascular factors, such as white matter lesions, confer an increased risk for depression (O’Brien et al., 2000) and apathy (Starkstein et al., 1997). In support of the link between depression and cerebrovascular disease are studies reporting depressive symptoms to be 1.5 to 2.5 times more prevalent in VaD than AD (e.g., Alexopoulos, 2003; Ballard et al., 2000; Lyketsos et al., 2000). Poor overall health has also been associated with NPS in AD, including depression (Chan et al., 2003), irritability, agitation, aggression, and disinhibition (Steinberg et al., 2006).

Most studies examining vascular conditions as risk factors for NPS in AD have relied on clinic-based samples, an approach that limits generalizability. Furthermore, only a small number have controlled for dementia severity. This is an important factor to consider, as some disturbances vary in prevalence by stage of disease (e.g., Lopez et al., 2003; Ferretti et al., 2001). The purpose of the current investigation was to examine whether the presence of vascular conditions or risk factors prior to dementia onset predicts the development of NPS in a population-based sample of individuals with incident AD. This is among the first studies to examine the vascular antecedents of NPS among individuals with AD in a population. Previous investigations with the Cache County cohort have reported prevalence rates, clustering, and risk factors for NPS in AD (Steinberg et al., 2006; Lyketsos et al., 2001; Lyketsos et al., 2000). These studies utilized the prevalence dementia sample from the Cache County Study, and the present investigation is restricted to incident AD.


Participant Screening

The Cache County Study on Memory, Health, and Aging (CCMS) is a longitudinal cohort study of AD and other dementias. Selection methods for participants in the CCMS have been reported in detail elsewhere (Miech et al., 2002; Lyketsos et al., 2000; Breitner et al., 1999). Briefly, eligible members of the population, defined as all permanent residents of Cache County, Utah aged 65 or older on January 1, 1995, underwent a multistage screening and assessment protocol. Individuals with prevalent dementia were identified in the initial study wave (1995) and those with incident dementia were identified in two follow-up waves (1998–1999 and 2002–2004). The average duration between the first and second waves was 3.20 (SD=.21) years, while the average duration between the second and third waves was 4.33 (SD=.23). At each wave, participants were screened for dementia using a revision of the 100-point Modified Mini-Mental State Examination (3MS; Tschanz et al., 2002). Further cognitive screening was conducted using the Informant Questionnaire for Cognitive Decline in the Elderly (IQCODE; Jorm et al., 1989) for individuals who were unable to complete the 3MS or obtained a score below 60. In Waves I and II, individuals whose sensory- and education-adjusted screening scores fell below 87 (in Wave 2, 84 for those over age 80; Miech et al., 2002; Breitner et al., 1999) or IQCODE scores ≥ 3.27 were studied further using the Dementia Questionnaire (DQ; Silverman et al., 1986). Based on the results of the DQ, participants with suspected dementia or a dementia prodrome, as well as a designated subsample of individuals, were selected for a comprehensive clinical assessment conducted by a registered nurse and psychometric technician in the presence of a reliable informant. The designated subsample consisted of 19% of the participants and was drawn without replacement from the entire cohort, stratified by age and sex, and enriched for APOE E4 genotype (Hayden et al., 2006; Khachaturian, Gallo, & Breitner, 2000). The procedures for Wave III were similar to those of the first two waves, except that all participants with 3MS scores below 91, members of the designated subsample, and individuals over the age of 84 underwent a clinical assessment. Informants were available at the clinical assessment for all study participants in the present sample.

During the clinical assessment, the nurse administered an interview with the informant to ascertain medical, cognitive, and demographic history and a brief medical and neurological examination. The psychometric technician administered a neuropsychological test battery to the participant. All clinical assessment data were reviewed in initial diagnostic conferences by a geriatric psychiatrist, neuropsychologist, and the examining clinical team. Individuals with suspected dementia underwent follow-up laboratory testing and neuroimaging, in addition to an examination by a geriatric psychiatrist.

Assessment of Dementia and Dementia Severity

Dementia diagnoses for CCMS participants were assigned after review of all available information at consensus conferences comprised of experienced clinicians in geropsychiatry, neurology, and neuropsychology. Age of incident dementia onset was estimated based on a review of a chronology of symptoms systematically obtained from the informant interview at the clinical assessment. The team of diagnosticians estimated onset age as the age in which the participant met DSM-III-R criteria for dementia. The present investigation includes only individuals with Possible or Probable AD. Individuals with other dementias or mixed AD and Vascular Dementia were excluded from these analyses. The diagnoses of Possible or Probable AD followed National Institute of Neurological and Communicative Disorders and Alzheimer’s Disease and Related Disorders Association (NINCDS-ADRDA; McKhann et al., 1984). There were 101 individuals diagnosed with AD at the first, and 153 at the second incidence wave. Dementia severity was assigned using the Clinical Dementia Rating Scale (Hughes et al., 1982; Morris et al., 1993), considering six domains of cognitive and functional performance: memory, orientation, judgment, community, hobbies, and personal care. For the purpose of this investigation, global CDR ratings (ranging from 0–5) were grouped into three stages of severity: mild (CDR <= 1), moderate (CDR = 2), and severe (CDR >=3). Age of dementia onset was assigned as the age at which the individual unambiguously met DSM-III-R criteria for dementia.

Assessment of Neuropsychiatric Symptoms

At the clinical assessment visit, NPS were assessed using the Neuropsychiatric Inventory (NPI; Cummings et al., 1994). The NPI is a structured informant interview conducted with the dementia participant’s caregiver that is used to rate the participant on each of 10 domains of NPS during the previous month: delusions, hallucinations, agitation/aggression, depression/dysphoria, apathy/indifference, elation/euphoria, anxiety, disinhibition, irritability/lability, and aberrant motor behavior. For each symptom endorsed, the interviewer follows up with a series of questions to rate the frequency and severity of the disturbance (Cummings). For descriptive purposes, symptom severity was estimated by multiplying scores for frequency and severity within each NPI domain (e.g., Iverson et al., 2002; Cummings).

Assessment of Vascular Conditions, Demographics, and APOE Genotype

Lifetime medical health data were obtained from participants in Wave 1, and updated at each subsequent wave so that risk factor information was available antecedent to the age of dementia onset. Information about cerebrovascular disease and other vascular conditions was obtained through questions such as: “Has a doctor or nurse told you that you had a stroke?” For individuals who responded yes, follow-up questions regarding stroke severity and sequelae were then asked, including “Did one side of your body or one arm or leg become weaker than the other?” and “Did you lose the ability to speak or understand what was said to you for more than one day?” Cardiovascular conditions that preceded the onset of dementia were ascertained through direct questions for heart attack, coronary artery bypass graft (CABG), or chronic conditions such as diabetes, hypertension, and hyperlipidemia (elevated serum cholesterol). History of each condition was coded as a binary variable and number of each type of event (e.g., heart attack, stroke) was also recorded. The onset age of chronic vascular conditions and dates of acute events were also queried and updated at each wave, allowing for a determination that the condition occurred antecedent to dementia. The mean (SD) number of years between the last update of vascular conditions and dementia diagnosis was 0.72 (SD = 0.57).

Using data regarding medical history, medications, blood pressure measurements, and clinical exam obtained from the clinical assessment in each wave, an indication of each subject’s overall health was rated in a consensus between the research nurse, neuropsychologist, and geropsychiatrist using the General Medical Health Rating (GMHR; Lyketsos et al., 1999). The GMHR is a measure of general medical comorbidity developed specifically for use with dementia patients, and results in a rating on an ordinal scale of 1 (poor), 2 (fair), 3 (good), and 4 (excellent). It has been used successfully in the Cache County study to rate seriousness of co-morbidity, and has been associated with greater cognitive and functional impairment in people with dementia (Lyketsos et al, 2005). Buccal scrapings were collected from 4,932 participants (97%) for APOE genotyping at the initial wave.


In exploratory analyses, two-way associations in the form of chi square tests of independence and bivariate logistic regression procedures were examined between vascular conditions (independent variables) assessed prior to the onset of dementia and individual NPS (dependent variables) ascertained at the time of AD diagnosis. For those NPS found to be significantly associated with vascular risk factors in exploratory analyses, multivariate logistic regression models were used to examine the relationship of each vascular condition (stroke, hypertension, hyperlipidemia, heart attack or CABG, and diabetes) to the occurrence of the NPS, while adjusting for other vascular variables. Overall health, age, gender, education level, presence of the APOE E4 allele, and dementia severity (CDR score) were selected as covariates based on previous literature suggesting their association with NPS. Dementia severity was coded as an ordinal variable with three levels: mild (CDR ≤ 1), moderate (CDR = 2), and severe (CDR ≥ 3). The regression models were developed in the following manner. For each vascular condition and NPS found to be significantly associated in the bivariate analyses, a logistic regression model that included the independent variable (e.g., stroke) and the outcome of interest (e.g., depression) was estimated. Age, gender, education level, APOE, and dementia severity were then sequentially entered, followed by other vascular risk factors (e.g., hypertension, hyperlipidemia) theoretically linked to cerebrovascular disease. Finally, GMHR was entered, in order to control for overall health status. Each covariate was retained if its associated wald statistic was p<=.05. The final model was compared with the saturated model using the likelihood ratio test.


Demographic characteristics for the sample are in Table 1. The sample was predominantly female (68.1% versus 31.9% male). The mean age was 85.68 (SD=6.62), and participants ranged in age (68 to >89) at the time of dementia diagnosis. Specifically, 20.5% were under the age of 80, 49.2% were between 80 and 89, and 30.3% were over the age of 89. The mean educational attainment for the total sample was 13.27 (SD = 2.92) years and ranged from three years of formal education to doctoral level study, with over half (52.0%) having completed high school. The majority of participants (84.1%) were in the mild stage, 12.2% in the moderate stage, and 3.7% in the severe stage of dementia severity on the CDR. Mean duration of dementia at the time of assessment was 1.94 (SD = 1.31) years and ranged from less than one year to eight years.

Table 1
Summary of Demographic Characteristics

Table 2 displays the frequency and severity of behavioral disturbances observed. Over half (51.0%) of participants exhibited at least one NPS, the most common being depression (25.8%). Apathy (18.6%), irritability (17.7%), and delusions (17.3%) were also common. Elation was the least common, reported in fewer than 1% of participants; for this reason it was and excluded from later analyses. Also depicted in Table 2 are mean severity ratings. Severity of neuropsychiatric symptoms was generally mild, with scores on the 12-point NPI domain scales ranging from 2.00 for hallucinations to 4.52 for apathy.

Table 2
Frequency and Severity of Neuropsychiatric Symptoms

Among vascular conditions, hypertension was most common, present in 31.3%. Thirteen percent of participants reported a history of hyperlipidemia, while 12.7% reported a history of either heart attack or CABG. Stroke and diabetes were uncommon, with only 10.2% of participants reporting diabetes, and 4.5% reporting a history of stroke. With respect to overall health status, 56.9% of individuals were rated in fair to poor health and 43.1% in good to excellent health.

Chi-square tests revealed significant associations between several vascular variables and individual behavioral disturbances. Stroke was associated with delusions (χ2=6.29, df=1, p=0.01), depression (χ2=5.01, df=1, p=0.03), and apathy (χ2=5.94, df=1, p=0.02). Hypertension was associated with delusions (χ2=7.66, df=1, p=0.006), agitation/aggression (χ2=6.45, df=1, p=0.01), and anxiety (χ2=12.09, df=1, p=0.001). The remaining vascular conditions (diabetes, hyperlipidemia, and heart attack or CABG) were not significantly associated with any NPS. Overall health rating was not significantly associated with any of the behavioral disturbances.

In the logistic models, adjusting for other vascular variables, overall health, dementia severity, and demographic covariates (age, gender, education, and APOE), these associations remained significant. Stroke was associated with a higher risk of apathy (OR=4.48, CI(95)=1.28, 15.61, p=0.02), delusions (OR=4.76, CI(95)=1.33, 17.01, p=0.02) and depression (OR=3.87, CI(95)=1.13, 13.23, p=0.03). Hypertension was associated with greater odds of delusions (OR=2.34, CI(95)=1.16, 4.75, p=0.02), agitation/aggression (OR=2.82, CI(95)=1.24, 6.45, p=0.01), and anxiety (OR=4.10, CI(95)=1.58, 10.00, p=0.002).

Other factors associated with increased risk of NPS were age and dementia severity. Younger age was associated with a 4% to 9% increase in risk for anxiety, apathy, and depression. More severe dementia was associated with delusions (OR=2.21, CI(95)=1.21, 4.02, p=0.01), anxiety (OR=2.50, CI(95)=1.25, 5.01, p=0.008), and disinhibition (OR=3.44, CI(95)=1.56, 7.57, p=0.002). Note, however, that the latter are based on a small number of cases, as the majority of subjects were in the mild stage of dementia severity. Additionally, men were significantly more likely than women to experience disinhibition (OR=2.79, CI(95)=1.29, 13.66, p=0.02). Table 3 displays the results of the final regression models for the above relationships. Each behavioral disturbance was more likely to occur in the presence of the vascular condition. Presence of APOE E4 allele and education were not associated with any neuropsychiatric symptom. Results of the bivariate regression analyses for relationships that were not significant are depicted in Table 4. Note that due to small cell counts, logistic regression procedures could not be performed. In such cases, and Fisher’s Exact tests were conducted.

Table 3
Relationship of Vascular Risk Factors to Neuropsychiatric Symptoms in Participants with AD
Table 4
Odds Ratios and 95% Confidence Intervals for Non-Significant Relationships between Vascular Conditions and NPS


In this population-based study of AD, we found evidence to suggest that a history of stroke was associated with a 3–4 fold- increased risk of apathy, depression, or delusions, while hypertension was associated with a 2–3-fold increased risk of anxiety, agitation/aggression, and delusions. Diabetes, hyperlipidemia, and heart attack or CABG, and overall health rating were not significantly associated with any NPS. The odds of anxiety, depression, and apathy decreased with age, and odds of delusions were greater with increasing dementia severity.

The association of stroke with apathy is consistent with the results of previous studies (e.g., Angelelli et al., 2004; Okada et al., 1997; Starkstein et al., 1997) and may reflect stroke-related damage to areas of the prefrontal cortex or related neural pathways, involved in the planning and execution of goal-directed behavior. This conclusion is supported by previous associations between apathy and dysfunction in prefrontal and anterior temporal brain regions (Okada et al., 1997; Craig et al., 1996). Cerebrovascular disease has previously been linked to depression in several studies of individuals with dementia (e.g., O’Brien et al., 2000; Hargrave et al., 2000). Studies reporting depressive symptoms to be 1.5 to 2.5 times more prevalent in VaD than AD (e.g., Alexopoulos, 2003; Ballard et al., 2000; Lyketsos et al., 2000) also suggest a vascular role in the development of depression.

Few studies have examined the relationship between stroke or hypertension and psychotic symptoms in dementia. One might speculate that vascular conditions lead to dysfunction in brain regions involved in psychotic symptoms. Hypertension is a known risk factor for stroke, which may result in lesions or affect the neural circuitry in the temporal lobe, thought to be involved in the production of delusions (Lopez et al., 2001; Geroldi et al., 2000). Alternatively, psychotic symptoms may occur as a side effect of antihypertensive medications (e.g., Ahmad, 1996). Bassiony et al. (2000) reported that delusions and hallucinations in AD were associated with the use of antihypertensive medications. It is possible that the side effects of antihypertensive medications become more salient in these patients due to reduced neural reserves associated with dementia. However, in the Cache County population, there was no relationship between antihypertensive use and psychotic symptoms (data not shown).

The observed relationship between hypertension and anxiety is consistent with previous research with individuals without dementia (e.g., McLaughlin et al., 2003; Mehta et al., 2003). The association between hypertension and agitation/aggression has not been studied previously, however. It may be that agitation is simply an expression of anxiety in persons with dementia.

Overall health was not associated with any NPS, in contrast to previous studies supporting a relationship between poor general health and various NPS (Tran et al., 2006; Chan et al., 2003). However, these studies did not differentiate between dementia subtypes, and dementias due to vascular pathology generally carry greater medical burden than AD. Our sample of incident AD cases exhibited low levels of medical comorbidity, with fewer than 40% reporting more than one physical illness. The finding that physical health is associated with depression in Vascular Dementia but not in AD (Ballard et al., 1996) supports this conclusion. A previous study of prevalent dementia from this population (Steinberg et al., 2006) found worse general health to be associated with agitation, irritability, disinhibition, and aberrant motor behavior. In contrast to the present focus on incident AD cases, differences in results may reflect the inclusion of other forms of dementia and greater disease severity and longer dementia duration associated with prevalent samples in the previous study.

Various limitations merit discussion. First, in order to capture risk factors antecedent to dementia onset, the vascular conditions and risk factor information of some participants were based on reports from up to two years before the dementia diagnosis. Specifically, the presence of a risk factor was only taken into account if it was present at the interview session prior to the assessment at which dementia was diagnosed. Although this interval was under two years for all but four participants (98%), this conservative approach may have led to the omission of some emergent conditions and biased the results toward the null. Second, the statistical analyses involved multiple comparisons, raising the possibility of Type I error rates. As this study was exploratory in nature, the findings require replication in other populations. Third, given that this study was cross-sectional with retrospective examination of vascular risk factors, we did not examine losses to follow-up. Our results are conditioned upon people with dementia who lived and were therefore able to participate in the study. Since dementia was only ascertained every three years, it is possible that individuals with a more virulent form of dementia who died prior to being assessed for NPS may be missing from the analyses. Fourth, each NPS was examined in terms of its presence or absence; severity or intensity of individual symptoms was not considered. Thus a “dose response” relationship could not be established. However, since most NPI disturbances in this sample were in the mild range, an examination of the relationship of vascular conditions to the severity of neuropsychiatric symptoms was not possible. Fifth, there was a certain degree of overlap among NPS, with approximately 30% of individuals suffering from two or more NPS. A previous study with this population underscored the presence of clusters of NPS or syndromes (Lyketsos et al., 2001), providing a compelling argument for the need to study psychiatric symptoms in the context of other disturbances. Future research should therefore consider how vascular conditions are related to neuropsychiatric syndromes as opposed to individual disturbances. Finally, some caution should be taken when attempting to generalize the results to other populations, particularly those with different ethnic backgrounds and different prevalence of vascular risk factors.

Despite these limitations, this study has several advantages, including the population-based sample, which limits concerns about referral bias, the thorough assessment and diagnosis of dementia, high participation rates among participants and informants, and the availability of data on vascular risk factors and conditions that preceded the onset of dementia.

In sum, several vascular conditions appear to confer an increased risk for NPS in AD. Knowledge gained from this investigation may assist clinicians in preparing patients and caregivers for the occurrence of psychiatric symptoms in the presence of multiple vascular conditions and in minimizing associated health risks.


This research was supported by National Institute on Aging grants R01AG21136, R01AG11380 and R01AG18712. We wish to thank Dr. Truls Ostbye for his thoughtful review of this manuscript. We are grateful to the neurogenetics laboratory of the Bryan Alzheimer’s Disease Research Center at Duke University for the APOE genotyping, and to Cara Brewer, BA, Tony Calvert, BSC, Michelle McCart, BA, Tiffany Newman, BA, Roxane Pfister, MA, Nancy Sassano, PhD, and Joslin Werstack, BA for expert technical assistance. Other Cache County Study of Memory, Health, and Aging Investigators include: James Anthony, PhD, Erin Bigler, PhD, MPH, Ron Brookmeyer, PhD, James Burke, MD, MPH, Eric Christopher, MD, Jane Gagliardi, MD, Michael Helms, Christine Hulette, MD, Liz Klein, MPH, Carol Leslie, MS, Lawrence Mayer, MD, John Morris, MD, Ronald G. Munger, PhD MPH, Chiadi Onyike, MD, MHS, Truls Ostbye, MD, PhD, MPH, Ron Petersen, MD, Kathy Piercy, PhD, Carl Pieper, DrPH, Brenda Plassman, PhD, Pritham Raj, MD, Russell Ray, MS, Linda Sanders, MPH, Ingmar Skoog, MD, David Steffens, MD, MHS, Marty Toohill, PhD, Leslie Toone, MS, Jeannette Townsend, MD, Lauren Warren, Michael Williams, MD, and Bonita Wyse, PhD.

Neuropsychological testing and clinical assessment procedures were developed by Drs. Welsh-Bohmer and Breitner. Dr. Tschanz provided training and oversight of all field staff and reviewed all individual neuropsychological test results to render professional diagnoses. The board-certified or board-eligible geriatric psychiatrists or neurologists who examined the study members included Drs Steinberg, Breitner, Steffens, Lyketsos, and Green. Dr. Williams also examined several subjects and provided expert neurologic consultation. Autopsy examinations were conducted by Dr. Townsend. Ms. Leslie coordinated the autopsy enrollment program. Diagnosticians at the expert consensus conferences included Drs Breitner, Burke, Lyketsos, Plassman, Steffens, Steinberg, Tschanz, and Welsh-Bohmer.

Description of Authors’ Roles

K. Treiber and J. Tschanz were responsible for formulating research questions, designing the study, conducting data analyses, and drafting and revising the article. C. Corcoran assisted with study design and provided expertise in statistical analyses. C. Lyketsos, M. Norton, and P. Rabins provided input into formulating research questions and study design, and critically reviewed the article for intellectual content. D. Stein assisted with study design and offered critical input. M. Steinberg, R. Green, K. Welsh-Bohmer, and J. Breitner were involved in the study design, and identifying cases of dementia.


Conflict of Interest Declaration

No conflicts of interest have been identified.


  • Ahmad S. Losartan and reversible psychosis. Cardiology. 1996;87:569–570. [PubMed]
  • Alexopoulos GS. Vascular disease, depression, and dementia. Journal of the American Geriatrics Society. 2003;15:1178–1180. [PubMed]
  • American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3rd Edition Revised. Washington, DC: Author; 1987.
  • Angelelli P, Paolucci S, Bivona U, Piccardi L, Ciurli P, Cantagallo A, Antonucci G, Fasotti L, Di Santantonio A, Grasso MG, Pizzamiglio L. Development of neuropsychiatric symptoms in poststroke patients: A cross-sectional study. Acta Psychiatrica Scandinavica. 2004;110:55–63. [PubMed]
  • Ballard C, Bannister C, Solis M, Oyebode F, Wilcock G. The prevalence, associations and symptoms of depression amongst dementia sufferers. Journal of Affective Disorders. 1996;36:135–144. [PubMed]
  • Ballard C, Neill D, O’Brien J, McKeith IG, Ince P, Perry R. Anxiety, depression and psychosis in VaD: Prevalence and associations. Journal of Affective Disorders. 2000;59:97–106. [PubMed]
  • Bassiony MM, Steinberg MS, Warren A, Rosenblatt A, Baker AS, Lyketsos CG. Delusions and hallucinations in AD: Prevalence and clinical correlates. International Journal of Geriatric Psychiatry. 2000;15:99–107. [PubMed]
  • Bassiony MM, Warren A, Rosenblatt A, Baker A, Steinberg M, Steele CD, Sheppard JM, Lyketsos CG. The relationship between delusions and depression in Alzheimer’s disease. International Journal of Geriatric Psychiatry. 2002;17:549–556. [PubMed]
  • Beeri MS, Werner P, Davidson M, Noy S. The cost of behavioral and psychological symptoms of dementia (BPSD) in community dwelling AD patients. International Journal of Geriatric Psychiatry. 2002;17:403–408. [PubMed]
  • Boyle PA, Malloy PF, Salloway S, Cahn-Weiner DA, Cohen R, Cummings JL. Executive dysfunction and apathy predict functional impairment in Alzheimer’s disease. American Journal of Geriatric Psychiatry. 2003;11:214–221. [PubMed]
  • Breitner JC, Wyse BW, Anthony JC, Welsh-Bohmer KA, Steffens DC, Norton MC, Tschanz JT, Plassman BL, Meyer MR, Skoog I, Khachaturian A. APOE-epsilon4 count predicts age when prevalence of AD increases, then declines: The Cache County Study. Neurology. 1999;53:321–331. [PubMed]
  • Brodaty H, Draper B, Saab D, Low LF, Richards V, Paton H, Lie D. Psychosis, depression and behavioural disturbances in Sydney nursing home residents: Prevalence and predictors. International Journal of Geriatric Psychiatry. 2001;16:504–512. [PubMed]
  • Burns A, Jacoby R, Levy R. Psychiatric phenomena in Alzheimer’s disease. British Journal of Psychiatry. 1990;157:72–94. [PubMed]
  • Chan DC, Kasper JD, Black BS, Rabins PV. Prevalence and correlates of behavioral and psychiatric symptoms in community-dwelling elders with dementia or mild cognitive impairment: The Memory and Medical Care Study. International Journal of Geriatric Psychiatry. 2003;18:174–182. [PubMed]
  • Copeland MP, Daly E, Hines V, Mastromauro C, Zaitchik D, Gunther J, Albert M. Psychiatric symptomatology and prodromal AD. Alzheimer Disease and Associated Disorders. 2003;17:1–8. [PubMed]
  • Craig AH, Cummings JL, Fairbanks L, Itti L, Miller BL, Li J, Mena I. Cerebral blood flow correlates of apathy in Alzheimer’s disease. Archives of Neurology. 1996;53:1116–1120. [PubMed]
  • Craig D, Hart DJ, McCool K, McIlroy SP, Passmore AP. Apolipoprotein E E4 allele influences aggressive behaviour in Alzheimer’s disease. Journal of Neurology, Neurosurgery, and Psychiatry. 2004;75:1327–1330. [PMC free article] [PubMed]
  • Craig D, Mirakhur A, Hart DJ, McIlroy SP, Passmore AP. A cross-sectional study of neuropsyhiatric symptoms in 435 patients with Alzheimer’s disease. American Journal of Geriatric Psychiatry. 2005;13:460–468. [PubMed]
  • Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The neuropsychiatric inventory. Comprehensive assessment of psychopathology in dementia. Neurology. 1994;24:2308–2314. [PubMed]
  • Danhauer SC, McCann JJ, Gilley DW, Beckett LA, Bienias JL, Evans DA. Do behavioral disturbances in persons with Alzheimer’s disease predict caregiver depression over time? Psychology and Aging. 2004;19:198–202. [PubMed]
  • Ferretti L, McCurry SM, Logsdon R, Gibbons L, Teri L. Anxiety and AD. Journal of Geriatric Psychiatry and Neurology. 2001;14:52–58. [PubMed]
  • Finkel S. Introduction to behavioural and psychological symptoms of dementia (BPSD) International Journal of Geriatric Psychiatry. 2000;15:S2–S4. [PubMed]
  • Gabryelewicz T, Religa D, Styczynska M, Peplonska B, Pfeffer A, Wasiak B, Luczywek E, Golebiowski M, Androsiuk W, Czyzewski K, Przekop I, Barcikowska M. Behavioural pathology in AD with special reference to Apolipoprotein E genotype. Dementia and Geriatric Cognitive Disorders. 2002;14:208–212. [PubMed]
  • Geroldi C, Akkawi NM, Galluzzi S, Ubezio M, Binetti G, Zanetti O, Trabucchi M, Frisoni GB. Temporal lobe asymmetry in patients with Alzheimer’s disease with delusions. Journal of Neurology, Neurosurgery, and Psychiatry. 2000;69:197–191. [PMC free article] [PubMed]
  • Gilley DW, Wilson RS, Bienias JL, Bennett DA, Evans DA. Predictors of depressive symptoms in persons with AD. Journal of Gerontology. 2004;59B:P75–P83. [PubMed]
  • Hargrave R, Geck LC, Reed B, Mungas D. Affective behavioural disturbances in Alzheimer’s disease and ischaemic vascular disease. Journal of Neurology, Neurosurgery, and Psychiatry. 2000;68:41–46. [PMC free article] [PubMed]
  • Harwood DG, Barker WW, Ownby RL, Duara R. Clinical characteristics of community-dwelling black AD patients. Journal of the National Medical Association. 2000;92:424–429. [PMC free article] [PubMed]
  • Hayden KM, Zandi PP, Lyketsos CG, Khachaturian AS, Bastian LA, Charoonruk G, Tschanz JT, Norton MC, Pieper CF, Munger RG, Breitner JCS, Welsh-Bohmer KA. Vascular risk factors for incident Alzheimer disease and vascular dementia. The Cache County Study. Alzheimer Disease and Associated Disorders. 2006;20:93–100. [PubMed]
  • Hirono N, Mori E, Yasuda M, Imamura T, Shimomura T, Hashimoto M, Tanimukai S, Kazui H, Yamashita H. Lack of effect of apolipoprotein E E4 allele on neuropsychiatric manifestations in Alzheimer’s disease. Journal of Neuropsychiatry and Clinical Neurosciences. 1999;11:66–70. [PubMed]
  • Holtzer R, Tang MX, Devanand DP, Albert SM, Wegesin DJ, Marder K, Bell K, Albert M, Brandt J, Stern Y. Psychopathological features in AD: Course and relationship with cognitive status. Journal of the American Geriatrics Society. 2003;51:953–960. [PubMed]
  • Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. British Journal of Psychiatry. 1982;140:566–572. [PubMed]
  • Ikeda M, Fukuhara R, Shigenobu K, Hokoishi K, Maki N, Nebu A, Komori K, Tanabe H. Dementia associated mental and behavioural disturbances in elderly people in the community: Findings from the first Nakayama study. Journal of Neurology, Neurosurgery, & Psychiatry. 2004;75:146–148. [PMC free article] [PubMed]
  • Iverson GL, Hopp GA, DeWolfe K, Solomons K. Measuring change in psychiatric symptoms using the Neuropsychiatric Inventory: Nursing Home version. International Journal of Geriatric Psychiatry. 2002;17:438–443. [PubMed]
  • Jorm J, Jacomb P. The informant questionnaire on cognitive decline in the elderly (IQCODE): socio-demographic correlates, reliability, validity and some norms. Psychol Med. 1989;19:1015–1022. [PubMed]
  • Khachaturian AS, Gallo JJ, Breitner JCS. Performance characteristics of a two-stage dementia screen in a population sample. Journal of Clinical Epidemiology. 2000;53:531–540. [PubMed]
  • Leroi I, Voulgari A, Breitner JCS, Lyketsos CG. The epidemiology of psychosis in dementia. American Journal of Geriatric Psychiatry. 2003;11:83–91. [PubMed]
  • Levenstein S, Smith MW, Kaplan GA. Psychosocial predictors of hypertension in men and women. Archives of Internal Medicine. 2001;28:1341–1346. [PubMed]
  • Levy ML, Cummings JL, Fairbanks LA, Sultzer DL, Small GW. Apolipoprotein E genotype and noncognitive symptoms in Alzheimer’s disease. Biological Psychiatry. 1999;45:422–425. [PubMed]
  • Lopez OL, Becker JT, Sweet RA, Klunk W, Kaufer DI, Saxton J, Habeych M, DeKosky ST. Psychiatric symptoms vary with the severity of dementia in probable AD. Journal of Neuropsychiatry and Clinical Neurosciences. 2003;15:346–353. [PubMed]
  • Lopez OL, Smith G, Becker JT, Meltzer CC, DeKosky ST. The psychotic phenomenon in probable Alzheimer’s disease: a positron emission tomography study. Journal of Neuropsychiatry and Clinical Neurosciences. 2001;13:50–55. [PubMed]
  • Lyketsos CG, Galik E, Steele C, Steinberg M, Rosenblatt A, Warren A, Sheppard JM, Baker A, Brandt J. The General Medical Health Rating (GMHR): A bedside global rating of medical comorbidity in patients with dementia. Journal of the American Geriatrics Society. 1999;47:487–491. [PubMed]
  • Lyketsos CG, Sheppard JM, Steinberg M, Tschanz JA, Norton MC, Steffens DC, Breitner JC. Neuropsychiatric disturbances in Alzheimer’s disease clusters into three groups: the Cache County study. International Journal of Geriatric Psychiatry. 2001;16:1043–1053. [PubMed]
  • Lyketsos CG, Steinberg M, Tschanz JT, Norton MC, Steffens DC, Breitner JC. Mental and behavioral disturbances in dementia: Findings from the Cache County Study on Memory in Aging. American Journal of Psychiatry. 2000;157:708–714. [PubMed]
  • Lyketsos CG, Toone L, Tschanz J, Rabins PV, Steinberg M, Onyike CU, Corcoran C, Norton M, Zandi P, Breitner JC, Welsh-Bohmer K, Anthony J, Ostbye T, Bigler E, Pieper C, Burke J, Plassman B, Green RC, Steffens DC, Klein L, Leslie C, Townsend JJ, Wyse BW, Munger R, Williams M. Population-based study of medical comorbidity in early dementia and “cognitive impairment, no dementia (CIND)“: association with functional and cognitive impairment: The Cache County Study. American Journal of Geriatric Psychiatry. 2005;13:656–664. [PubMed]
  • McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer’s disease. Neurology. 1984;34:939–944. [PubMed]
  • McLaughlin T, Geissler EC, Wan GJ. Comorbidities and associated treatment charges in patients with anxiety disorders. Pharmacotherapy. 2003;23:1251–1256. [PubMed]
  • Mehta KM, Simonsick EM, Penninx BW, Schulz R, Rubin SM, Satterfield S, Yaffe K. Prevalence and correlates of anxiety symptoms in well-functioning older adults: Findings from the health aging and body composition study. Journal of the American Geriatrics Society. 2003;51:499–504. [PubMed]
  • Miech R, Breitner J, Zandi P, Khachaturian A, Anthony JC, Mayer L. Incidence of AD may decline in the early 90s for men, later for women: the Cache County study. Neurology. 2002;58:209–218. [PubMed]
  • Morris JC, Ernesto C, Schafer K, Coats M, Leon S, Sano M, Thal LJ, Woodbury P. Clinical Dementia Rating training and reliability in multicenter studies: The Alzheimer’s Disease Cooperative Study experience. Neurology. 1997;48:1508–1510. [PubMed]
  • O’Brien J, Perry R, Barber R, Gholkar A, Thomas A. The association between white matter lesions on magnetic resonance imaging and noncognitive symptoms. Annals of the New York Academy of Sciences. 2000;903:482–489. [PubMed]
  • Okada K, Kobayashi S, Yamagata S, Takahashi K, Yamaguchi S. Poststroke apathy and regional cerebral blood flow. Stroke. 1997;28:2437–2441. [PubMed]
  • Orrell M, Bebbington P. Psychosocial stress and anxiety in senile dementia. Journal of Affective Disorders. 1996;39:165–173. [PubMed]
  • Paulsen JS, Salmon DP, Thal LJ, Romero R, Weisstein-Jenkins C, Galasko D, Hofstetter CR, Thomas R, Grant I, Jeste DV. Incidence of and risk factors for hallucinations and delusions in patients with probable AD. Neurology. 2000;54:1965–1971. [PubMed]
  • Rockwell E, Jackson E, Vilke G, Jeste D. A study of delusions in a large cohort of AD patients. American Journal of Geriatric Psychiatry. 1994;2:157–164.
  • Silverman JM, Breitner JCS, Mohs RC, Davis KL. Reliability of the family history method in genetic studies of Alzheimer’s disease and related dementias. American Journal of Psychiatry. 1986;143:1279–1282. [PubMed]
  • Starkstein SE, Jorge R, Mizrahi R, Robinson RG. A prospective longitudinal study of apathy in Alzheimer’s disease. Journal of Neurology, Neurosurgery, and Psychiatry. 2006;77:8–11. [PMC free article] [PubMed]
  • Starkstein SE, Petracca G, Chemerinski E, Kremer J. Syndromic validity of apathy in AD. American Journal of Psychiatry. 2001;158:872–877. [PubMed]
  • Starkstein SE, Sabe L, Vazquez S, Di Lorenzo G, Martinez A, Petracca G, Teson A, Chemerinski E, Leiguarda R. Neuropsychological, psychiatric, and cerebral perfusion correlates of leukoaraiosis in AD. Journal of Neurology, Neurosurgery, and Psychiatry. 1997;63:66–76. [PMC free article] [PubMed]
  • Steinberg M, Corcoran C, Tschanz JT, Huber C, Welsh-Bohmer K, Norton MC, Zandi P, Breitner JC, Steffens DC, Lyketsos CG. Risk factors for neuropsychiatric symptoms in dementia: the Cache County Study. International Journal of Geriatric Psychiatry. 2006;21:824–830. [PubMed]
  • Tran P, Schmidt K, Gallo J, Tuppo E, Scheinthal S, Chopra A, Libon DJ. Neuropsychiatric symptoms and medical illness in patients with dementia: an exploratory study. Journal of the American Osteopathic Association. 2006;106:412–414. [PubMed]
  • Tsai SJ, Hwang JP, Yang CH, Liu KM. Physical aggression and associated factors in probable AD. Alzheimer Disease and Associated Disorders. 1996;10:82–85. [PubMed]
  • Tschanz J, Welsh-Bohmer K, Plassman B, Norton M, Wyse B, Breitner J. An adaptation of the Modified Mini-Mental State Examination: Analysis of demographic influences and normative data. The Cache County Study. Neuropsychiatry, Neuropsychology, and Behavioral Neurology. 2002;58:28–38. [PubMed]
  • Van der Flier WM, Staekenborg S, Pijnenburg YA, Gillissen F, Romkes R, Kok A, Bouwman FH, Scheltens P. Apolipoprotein E genotype influences presence and severity of delusions and aggressive behavior in Alzheimer disease. Dementia and Geriatric Cognitive Disorders. 2007;23:42–46. [PubMed]